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BACKGROUND: Guidelines now discourage opioid analgesics for chronic non-cancer pain 
because the benefits frequently do not outweigh the harms. 
OBJECTIVES: To determine the proportion of patients with chronic non-cancer pain who are 
prescribed an opioid, the types prescribed, and factors associated with prescribing.  
METHODS: Database searches were conducted from inception to 29th October 2018 without 
language restrictions. We included observational studies of adults with chronic non-cancer 
pain measuring opioid prescribing. Opioids were categorized as weak (e.g. codeine) or 
strong (e.g. oxycodone). Study quality was assessed using a risk of bias tool designed for 
observational studies measuring prevalence. Individual study results were pooled using a 
random-effects model. Meta-regression investigated study-level factors associated with 
prescribing (e.g. sampling year, geographic region as per World Health Organization). The 
overall evidence quality was assessed using Grading of Recommendations Assessment, 
Development and Evaluation criteria.  
RESULTS: Of the 42 studies (5,059,098 participants) identified, majority (n = 28) from the 
United States of America. Eleven studies were at low risk of bias. The pooled estimate of the 
proportion of patients with chronic non-cancer pain prescribed opioids was 30.7% (95%CI 
28.7% to 32.7%, 42 studies, moderate-quality evidence). Strong opioids were more 
frequently prescribed than weak (18.4% (95%CI 16.0% to 21.0%, n = 15 studies, low-quality 
evidence), versus 8.5% (95%CI 7.2% to 9.9%, n = 15 studies, low-quality evidence)). Meta-
regression determined opioid prescribing was associated with year of sampling (more 
prescribing in recent years) (p = 0.014) and not geographic region (p = 0.056).  
CONCLUSION: Opioid prescribing for patients with chronic non-cancer pain is common and 
has increased over time. 
 




Global opioid prescribing doubled between 2001–03 and 2011–13 [1]. Several developed 
countries have noted substantial increases in opioid prescriptions including the United States 
of America (USA) [2], Canada [3], United Kingdom (UK) [4], Scotland [5] and Australia [6], 
and also for some strong prescription opioids such as oxycodone [2, 5-10].   
 
Chronic non-cancer pain is a common problem and can be due to a range of conditions 
including chronic low back pain and osteoarthritis. Estimates of the prevalence of chronic 
pain vary considerably according to the approach used [11]. Population-based studies report 
that one in five (20.4% (95% CI 19.7% to 21.0%) adults in the USA and nearly a half of UK 
adults (pooled estimate 43.5%, 95% CI 38.4% to 48.6%) have chronic non-cancer pain [12, 
13]. Individuals with chronic pain have a poorer quality of life and report greater disability and 
depression than other people in the community [14]. Chronic pain costs billions of dollars 
each year in healthcare costs and lost work productivity [15].  
 
Opioid analgesics are often used to manage chronic non-cancer pain [4]. Previously, opioids 
were considered an appropriate strategy to manage chronic non-cancer pain. Increases in 
opioid prescribing, particularly in the USA, came after campaigns promoting the safety of 
chronic opioid use. Opioid use was also encouraged by the initiative to consider pain as the 
5th vital sign [16]. However, there is now greater appreciation of the harms associated with 
prescription opioid analgesics [17] and guidelines, such as those from The Centres for 
Disease Control and Prevention Guideline for Prescribing Opioids for Chronic Pain [17] now 
discourage the use of opioid analgesics. Furthermore, opioids are now not recommended for 
the management of some specific pain conductions such as chronic low back pain [18].  
 
The proportion of patients with chronic non-cancer pain, including chronic low back pain, 
who are prescribed opioids is not well understood. Opioid prescribing data has been 
reported from individual health care settings [19-23]. However, there are no systematic 
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reviews that have synthesized these data in the chronic non-cancer pain population. 
Additionally, factors such as clinical setting or specialities which may be considered 
contributors to high opioid prescribing rates [24-27] have not been systematically evaluated 
within a chronic non-cancer pain population. Determining the proportion of patients with 
chronic non-cancer pain prescribed opioid analgesics provides a benchmark to help assess 
if prescription reduction strategies have been successful. Therefore, the aim of our 
systematic review was to determine how common opioid prescribing is for chronic non-
cancer pain. Our secondary aims included examining the types of opioids prescribed; 
determining any factors associated with prescribing such as clinical setting, geographic 
location and the time period of the study; and determining how common opioid prescribing 
is, the types of opioids prescribed and factors associated with prescribing in the chronic low 
back pain population.  
 
METHODS  
This review was devised in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement guidelines [28] and Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) checklist [29], and registered on 
PROSPERO (CRD42017063954; www.crd.york.ac.uk).  
  
Eligibility 
We included observational studies (cross-sectional, cohort or case-control studies) of adults 
(18+ years) with chronic non-cancer pain that were prescribed opioid analgesics for pain 
management. We included population-based studies (such as databases, including 
dispensing data), studies from clinical settings (i.e. primary (e.g. general practitioner), 
secondary (e.g. hospital, emergency department and medical specialists) or tertiary care 
settings (e.g. multidisciplinary pain treatment programs). We included studies that defined 
chronic non-cancer pain as pain in one or more body locations of non-cancerous origin for at 
least three months. We excluded studies that were not considered to be a representative 
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sample (i.e. not sampling consecutive cases or randomly sampled population), self-report of 
opioid use, and studies involving only pregnant women. 
 
Search strategy 
We searched PubMed (NLM® database), MEDLINE (OvidSP), EMBASE (OvidSP), Web of 
Science (Thomson Reuters), International Pharmaceutical Abstracts (via OvidSP) databases 
up to 29th October 2018 with no language restrictions using terms such as “opioid analgesic” 
and “chronic non-cancer pain”. The full search strategy is detailed in Appendix 1. 
Additionally, we conducted backward and forward reference and author citation tracking, and 
communicated with content experts to identify any missing studies. 
 
Screening 
Two review authors (SM, GW) independently screened identified titles and abstracts to 
determine eligibility. Disagreements were resolved by discussion first, then arbitration by an 
independent third review author (CM) if needed. For articles written in languages that were 
unable to be read by the review authors, we asked colleagues to assist with reading and 
appraising the article. Individual review authors did not assess the eligibility of any studies to 
which they had contributed. We contacted study authors to confirm eligibility when 
necessary (five studies). 
  
Data extraction and management   
Two review authors from a panel of seven (SM, GW, CL, AM, RB, SP, MU) extracted data 
independently for each included study. Disagreements were resolved by discussion first, 
then arbitration by an independent third review author if necessary (CM). We contacted the 
authors of studies for clarification and additional data if relevant data were missing.  
 We used standardized and piloted data extraction forms. Information was extracted on 
bibliometric data, study characteristics (e.g. sampling dates, setting), participant 
characteristics (e.g. age, type and duration of chronic non-cancer pain), exposure (e.g. 
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number and type of opioids prescribed, if any medicines were co-prescribed with the opioid 
medicine) and data completeness (i.e. missing data). 
 
Medicines were classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system [30]. Opioid analgesics (N02A) were simplified into (i) weak single 
ingredient opioid analgesics (e.g. codeine, tramadol), defined as < 50 morphine milligram 
equivalents (MME) per day; (ii) strong single ingredient opioid analgesics (e.g. tapentadol, 
oxycodone, morphine, pethidine, fentanyl, hydromorphone, buprenorphine), defined as ≥ 50 
MME per day; and (iii) combination opioid analgesics. Medicines in the latter category were 
categorized based on the strongest medicine present in the combination, either as a weak 
combination opioid analgesic or strong combination opioid analgesic. Opioid classification is 
presented in Appendix 2. Opioid analgesic medicines were converted to MME dose to 
facilitate comparison and interpretability following conversion by Dowell 2016 [17]. 
 
Countries were grouped according to World Health Organisation (WHO) regions of Africa, 
Americas (Northern, Central and Southern), Europe, South-East Asia, Eastern 
Mediterranean and Western Pacific [31]. Low, middle and high-income countries were 
classified as per the World Bank [32]. High-income countries include Andorra, Australia, 
Austria, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, 
Germany, Hungary, Iceland, Israel, Italy, Japan, Lichtenstein, Luxembourg, Malta, Monaco, 
Netherlands, New Zealand, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, 
Switzerland, UK and USA. As we found no studies originating from South America, the 
region of Americas refers to North America only. 
 
Risk of bias assessment  
Two reviewers from a panel of seven (SM, GW, CL, AM, RB, SP, MU) independently 
assessed the risk of bias of eligible studies and disagreements were resolved by discussion 
first, then arbitration by an independent third review author if necessary (CM). Risk of bias 
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was assessed using the modified risk of bias tool developed by Hoy et al which assesses the 
risk of bias of observational studies measuring prevalence [33]. The tool comprises four 
questions assessing external validity and six questions on internal validity with each question 
scores “yes” (low risk of bias) or “no” (high risk of bias). An overall judgment of bias risk is 
then rated as low, moderate or high. The risk of bias assessment criteria and scores are 




The flow of studies was summarized in a study flow diagram, following the PRISMA 
statement [28]. The results of the review were summarized both qualitatively as a narrative 
synthesis and quantitatively in a meta-analysis where possible. Study characteristics and 
participants were reported descriptively. Opioids prescribed and dichotomous variables are 
reported as proportions, n/N (%). Opioid prescribing was determined as the proportion of 
patients with chronic non-cancer pain that were prescribed opioids. Annual opioid 
prescribing data were used if available, and hence some studies have multiple, independent, 
opioid data presented per year. Opioid types were grouped as weak, strong, weak 
combination and strong combination opioids. Continuous outcomes were reported as means 
with 95% confidence interval (CI) (if to describe the precision of an estimate) or standard 
deviation (SD) (if to describe sample variability). Where possible, outcomes were converted 
to a common metric to facilitate comparison and interpretability e.g. opioid dose (MME/day).  
  
Study results were combined in a meta-analysis using a random-effects model irrespective 
of setting. Statistical heterogeneity was assessed by visual inspection of the forest plot (e.g. 
P values and overlapping CIs) and the I2 statistic. We followed the recommended guidance 
for interpretation of I2 as: 0% to 40%, might not be important; 30% to 60%, may represent 
moderate heterogeneity; 50% to 90%, may represent substantial heterogeneity; 75% to 
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100%, considerable heterogeneity. Where heterogeneity was present and the data could not 
be pooled, a narrative synthesis was conducted.  
 
We used meta-regression to investigate heterogeneity and study-level factors associated 
with opioid prescribing. The study-level factors included (i) WHO region (North America 
(reference), Europe, Western Pacific, South East Asia); (ii) if study funding was disclosed 
(yes (reference)/no); (iii) setting (primary (reference), secondary, tertiary, multiple settings 
(i.e. primary and tertiary), database (population-based study (e.g. Veterans Affairs database 
or insurance claims database)); (iv) the duration of sampling period (in months); (v) mid-point 
of the study period (year) which the opioid prescribing estimate was sampled. We planned, 
but there was insufficient data to assess patient-level factors within studies such as age, 
gender. We used 2-sided p-value, Knapp-Hartung and maximum likelihood method. 
Analyses were conducted in Comprehensive Meta-Analysis Program version 3. 
 
We used the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) approach [34] to provide a summary of the overall quality of evidence. The 
GRADE assessment criteria and scores are presented in Appendix 4. 
 
Subgroup analyses  
Subgroup analyses of the review’s aims were conducted confined to patients with chronic 
low back pain. Low back pain was defined as pain in the posterior aspect of the body from 
the lower margin of the twelfth ribs to the lower gluteal folds with or without pain referred into 
one or both lower limbs. 
 
Sensitivity analysis  
A sensitivity analysis was conducted with (i) high risk of bias studies removed, and (ii) 
tramadol classified as a ‘strong opioid’ rather than a ‘weak opioid’ to account for the 
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differences in scheduling between countries (e.g. tramadol is considered a ‘strong opioid’ in 




From 26,048 citations identified by the search, 269 full texts were screened, and 42 studies 
were eligible for inclusion (Figure 1). 
 
Included studies 
The majority of studies were from USA (n = 28) [37-64], followed by UK (n = 4 studies) [65-
68], Spain (n = 3 studies) [69-71] and Canada (n = 3 studies) [72-74], with single studies 
from Norway [22], Denmark [75], Australia [76] and India [77]. There were no studies that 
compared data from multiple countries. Other than the study from India [77], classed as a 
lower middle-income country, there were no studies from low or middle-income countries. 
Study sample sizes ranged from 143 patients [39] to a database of 4,175,765 patients [42]. 
Studies reported prescription data from 1991 to 2015 and were all published in English. 
Thirty-one studies (74%) were retrospective reviews of medical records across a range of 
settings (Table 1). 
 
There were 5,059,098 patients with chronic non-cancer pain across the forty-two studies. 
Twenty-seven studies (64%) included specific subgroups of chronic non-cancer pain such as 
chronic low back pain [44, 46, 47, 49, 53, 66], osteoarthritis [47, 54, 57, 58, 70, 72] 
rheumatoid arthritis [59, 60] and fibromyalgia [61-64, 73]. The mean age of participants was 
58.6 years (SD 13.1, n = 29 studies). The mean age of those prescribed an opioid analgesic 
was slightly younger at 55.7 years (SD 13.3, n = 11 studies). The mean pain intensity in 
patients with chronic non-cancer pain who were taking opioid analgesics was infrequently 
reported (6.0 out of 10 on a Numerical Pain Rating Scale, SD 1.8, n = 5 studies). Only four 
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studies reported when other analgesic medicines were co-prescribed with other analgesics 
at the time of opioid prescribing [22, 52, 59, 66].  
 
Risk of bias 
Eleven studies were found to have low risk of bias (26%). The majority of studies were 
considered to have moderate risk of bias (62%, n = 26 studies) with a small proportion of 
studies with high risk of bias (12%, n = 5 studies) (Appendix 3). The domain covering the 
reliability and validity of questionnaires used to measure prevalence was frequently at high 
risk of bias as most studies retrospectively reviewed site-specific medical records rather than 
using validated measures. 
 
Opioid analgesic prescribing estimates 
Proportion of patients with chronic non-cancer pain prescribed opioid analgesics  
The pooled estimate of opioid analgesic prescription for those with chronic non-cancer pain 
was 30.7% (95%CI 28.7% to 32.7%, n = 42 studies; moderate quality evidence) (Figure 2).  
 
Types of opioid analgesics prescribed to patients with chronic non-cancer pain 
Seventeen studies provided data on the type of opioid analgesics prescribed to patients with 
chronic non-cancer pain [38, 39, 41, 43, 44, 46, 54, 59, 60, 64, 68-70, 72, 73, 75, 76]. The 
pooled estimate of prescribing a weak opioid was 8.5% (95%CI 7.2% to 9.9%, n = 15 
studies; low quality evidence) [38, 39, 43, 44, 46, 54, 59, 60, 64, 69, 70, 72, 73, 75, 76], a 
strong opioid 18.4% (95%CI 16.0% to 21.0%, n = 15 studies; low quality evidence) [38, 39, 
41, 43, 46, 54, 59, 60, 68-70, 72, 73, 75, 76], a weak combination opioid 11.0% (95% CI 
6.6% to 17.8%, n = 4 studies; moderate quality evidence) [54, 69, 70, 76] and a strong 
combination opioid 24.1% (95%CI 7.8% to 54.4%, n= 2 studies; low quality evidence) [54, 




Proportion of patients with chronic low back pain prescribed and opioid analgesics 
and their types 
Twelve studies [41, 42, 44, 46, 47, 49, 52, 53, 56, 66, 71, 76] provided data on 758,248 
patients with chronic low back pain. Nine (75%) were from North America with single studies 
from UK [66], Australia [76], Spain [71]. The pooled estimate of opioid prescribing was 
41.5% (95%CI 28.9% to 55.4%, n = 12 studies; low quality evidence) (Appendix 5.2). A post-
hoc analysis of opioid prescribing was conducted stratified by condition (chronic pain, 
chronic back pain, fibromyalgia, chronic headache, inflammatory arthritides, neuropathic 
pain, osteoarthritis, chronic pain from spinal cord injury) and is presented in Appendix 5.3. 
Conditions of inflammatory arthridites (29.5% (95%CI 25.5% to 33.9%)) and osteoarthritis 
(27.3% (95%CI 24.3% to 30.5%)) had a similar estimate of opioid prescribing compared to 
all chronic non-cancer pain conditions. 
 
The specific types of opioids prescribed to patients with chronic low back pain was 
infrequently reported. We could determine that weak opioid analgesics were prescribed for 
11.0% of patients (95% CI 7.5% to 12.6%; moderate quality evidence) from one study [44] 
over the decade of 2000 to 2010. No studies provided data related to the number of 
participants taking strong opioid analgesics or combination opioid analgesics in patients with 
chronic low back pain.  
 
Factors associated with opioid analgesic prescribing  
Our meta-regression model explained 28% of the variance in the proportion of patients with 
chronic non-cancer pain prescribed an opioid (R2 = 0.28). The prescribing estimates were 
associated with the year of sampling (increasing over time, p = 0.014), no disclosure of 
funding (p = 0.047; higher opioid prescribing if a study did not provide a funding statement 
compared to studies that reported a funding statement), but not by WHO region (p = 0.056), 
setting (secondary, tertiary, database or multiple settings compared to primary care) (p = 
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0.955) or the duration of the sampling period in months (p = 0.103) (Appendix 6.1). The 
adjusted estimates of opioid prescribing over time are presented in Figure 3.  
 
A separate meta-regression model restricted to studies of chronic low back pain (n = 12 
studies) explained 82% of the variance in prescribing (R2 = 0.82). The prescribing estimates 
were affected by year of sampling (increasing over time, p = 0.001) but not WHO region (p = 
0.503), disclosure of funding (p = 0.365) or setting (p = 0.228) (Appendix 6.2). The adjusted 
estimates of opioid prescribing over time are presented in Appendix 6.3. 
 
Sensitivity analysis 
Removing the five studies at high risk of bias did not influence opioid prescribing estimates 
(30.4% (95%CI 28.3% to 32.6%, n = 37 studies) versus 30.7% (95%CI 28.7% to 32.7%, n = 
42 studies)). When tramadol was considered a ‘strong opioid’, there were small changes in 
the prescribing estimates: weak opioids reduced from 8.5% (95%CI 7.2% to 9.9%; n = 15 
studies) to 5.9% (95%CI 3.9% to 8.7%; n = 11 studies); strong opioids increased from 18.4% 
(95%CI 16.0% to 21.0%; n = 15) to 19.2% (95%CI 17.9% to 20.6%; n = 17 studies); weak 
combination opioids decreased from 11.0% (95%CI 6.6% to 17.8%; n = 4 studies) to 9.9% 
(95%CI 5.3% to 17.5%; n = 3 studies); and strong combination opioids decreased from 
24.1% (95%CI 7.8% to 54.4%; n = 2 studies) to 20.7% (95%CI 11.9% to 33.5%; n = 3 
studies). Post-hoc analyses explored if limiting data to the most recent available affected 
opioid estimates. Our approach of using all available data was more conservative. When the 
analysis only used data from recent years of all studies, the opioid prescribing estimate 
increased to 34.3% (95%CI 30.0% to 38.8%). 
  
DISCUSSION 
Our review established, primarily from published reports stemming from the USA, that 
almost one third of patients with chronic non-cancer pain are prescribed an opioid (31%). 
This estimate was even higher (42%) for patients with chronic low back pain. For chronic 
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non-cancer pain, stronger opioids are more commonly prescribed than weaker opioids, while 
the type of opioid was infrequently reported for patients with chronic low back pain. The year 
of prescribing (more recent) and the lack of funding statement was associated with 
prescribing to patients with chronic non-cancer pain but not influenced by WHO region, 
setting and study risk of bias. Time (more recent) was significantly associated with opioid 
prescribing for patients with chronic low back pain. 
 
Our review is the first to examine the frequency of prescribing of opioid analgesic to patients 
with chronic non-cancer pain across countries and potential factors associated with 
prescribing. An additional strength of our review is that we identified studies by a sensitive 
literature search, including using backwards and forward reference and author citation 
tracking. Of the included studies, some studies were of single-site clinics. However, sample 
representativeness was a specific eligibility criterion and evaluated in the risk of bias 
assessment. We acknowledge a weakness of the review is the range of chronic pain 
conditions and clinical settings included, which we addressed by using meta-regression to 
explore heterogeneity. We note the reporting of opioid prescriptions rarely included data 
related to dose and duration of treatment prescribed, and hence, we were unable to 
determine if the dosing regimens have changed over time. Understanding the types of 
opioids (i.e. weak versus strong) prescribed to patients with chronic low back pain remains 
unclear as only one study reported such detail. Additionally, our review can only summarize 
available data, and the availability and access to opioids varies between health care systems 
and countries [78]. 
 
The prescription of opioids across the globe differs. The high-income WHO regions of North 
America, Europe (western and central) and Oceania account for 95.7% of global opioid use 
but only represents approximately 15% of the world’s population [1]. We found from our 
studies that the prescription of opioids for chronic non-cancer pain is more commonly 
reported in these regions, but no studies compared data from multiple countries. However, 
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there is some uncertainty as only 11 of the 42 studies were from countries other than North 
America. Although our results show that opioids are being increasingly prescribed for chronic 
non-cancer pain over time, this is at odds with the pattern of general opioid use in some 
countries. For instance, reports from Scandinavian countries suggest stable opioid 
dispensing in Demark, Sweden and Norway between 2006 and 2014 [79], whereas in the 
UK, the prescribing of opioids in general practice doubled between 2000 and 2012 [80] then 
began to decline from 2016 to 2017 [19]. In the USA following reports in 2017 that the 
prescription of opioids is now a contributor to reduced life expectancy in the USA and their 
life expectancy is lower than most high-income countries [81], opioid mitigation strategies 
may have reduced opioid prescribing. A 2019 study noted a halving in the monthly incidence 
of initial opioid analgesics prescribed to opioid naïve enrolees of a USA   health insurer from 
1.63% of enrolees in July 2012 to 0.75% of enrolees in December 2017 [82]. The differences 
across health care systems such as government regulations regarding access to opioids, 
reimbursements and views on the role opioids play in chronic non-cancer pain management 
may contribute to the variation of opioid use across countries. 
 
The access to opioid analgesics in low to middle income countries, which account for 80% of 
the world’s population [83] is often limited, and pain is frequently undertreated [84]. Although 
recent population growth in low income and middle income regions has been the highest in 
Africa, Asia, and Latin America [85], we found only one study examining opioid prescribing 
for chronic non-cancer pain in a low or middle income country (India [77]). Although South-
East Asia being home to one-quarter of the world’s population [84], the consumption of 
opioids is low, partly due to tight government drug regulations restricting opioid access [84]. 
The prescription of opioids to patients with chronic non-cancer pain in other low- and middle-
income countries remains unclear.  
 
Meta-regression assessed potential study factors associated with opioid prescribing for 
patients with chronic non-cancer pain. One factor that did not influence opioid prescribing in 
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our review was setting, despite some reports suggesting that particular settings such as 
hospital discharge [86] and the surgical area contribute to the “opioid crisis” because of the 
absence of chronic non-cancer pain management in training curricula and the unnecessary 
prescription post-surgery [25, 87]. In pharmacy dispensing data from the USA, high volume 
opioid prescribers have been noted within the specialities of family medicine, internal 
medicine and orthopaedics [88] and payments from pharmaceutical companies influenced a 
higher volume of prescribing and of more expensive opioid analgesics [89]. We had 
insufficient data to assess sub-specialities and only forty percent of studies detailed the 
types of opioids prescribed (i.e. strong or weak). The prescription of some types of opioids 
such as oxycodone has increased over time [3, 5, 8, 9, 90], but our meta-regression analysis 
determined that year was not associated with the prevalence of weak, strong or combination 
opioid analgesics in patients with chronic non-cancer pain. The prescribing of opioids to 
patients with chronic low back pain significantly increased over time but other study level 
factors were unable to explain any associations of opioid prescribing in this population. 
 
One of our goals was to establish a baseline of how commonly opioids are prescribed for 
chronic non-cancer pain which may help determine the success of future opioid mitigation 
strategies. While we have sufficient data for this purpose for the USA, we have sparse or no 
data for other countries. Additionally, there were insufficient data on the dose and duration of 
opioids prescribed to patients with chronic non-cancer pain. Future research could begin to 
close these evidence gaps and evaluate if patients with chronic non-cancer pain receive low-
value pharmaceutical care. The ‘deprescribing’ of opioids needs to address reducing the 
initial prescription of opioids, but also how to support the cessation of opioids while still 
providing access to appropriate pain management. Opioid mitigation strategies have begun, 
for example, national initiatives [91], opioid stewardship programs[92, 93], and up-scheduling 
of codeine in Australia [94] and Italy [95]. However, research on opioid mitigation strategies 
specific to the needs of patients with chronic non-cancer pain is needed. The overuse of 
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Opioid prescribing for patients with chronic non-cancer pain is common and has increased 
over time, with stronger opioids more frequently prescribed than weaker opioids.  
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Figure 1: Study flow diagram. 
Figure 2: The proportion of patients with chronic non-cancer pain prescribed opioid 
analgesics. 
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Figure 2: The proportion of patients with chronic non-cancer pain prescribed opioid 
analgesics. 
Study name Events/Total Statistics for each study Risk of bias 
Event Lower Upper Relative 
Total rate limit limit p-Value weight
Jensen 200 64 / 160 0.400 0.327 0.478 0.012 1.32 Moderate 1991 Europe
Castillo 2016 96 / 569 0.169 0.140 0.202 0.000 1.42 Moderate 1995 North America
Mahowald 200 152 / 230 0.661 0.597 0.719 0.000 1.37 Moderate 1997 North America
Turk 1997 81 / 191 0.424 0.356 0.495 0.037 1.35 Moderate 1997 North America
AlMakadma 2013 526 / 1500 0.351 0.327 0.375 0.000 1.51 High 1998 Europe
Cowan 2003 104 / 1392 0.075 0.062 0.090 0.000 1.44 Moderate 1999 Europe
Dominick 2004 1248 / 3061 0.408 0.390 0.425 0.000 1.52 High 1999 North America
Mafi 2013 144 / 572 0.252 0.218 0.289 0.000 1.45 Moderate 1999 North America
Mafi 2015 68 / 352 0.193 0.155 0.238 0.000 1.38 Low 1999 North America
Clarke 2002 47 / 143 0.329 0.257 0.410 0.000 1.28 Moderate 2000 North America
Mapel 2004 16581 / 188452 0.088 0.087 0.089 0.000 1.53 Low 2000 North America
Steinman 2015 269 / 6559 0.041 0.036 0.046 0.000 1.50 Moderate 2000 North America
Gore 2007 3464 / 30999 0.112 0.108 0.115 0.000 1.53 Moderate 2001 North America
Mafi 2013 212 / 725 0.292 0.260 0.327 0.000 1.47 Moderate 2001 North America
Mafi  2015 98 / 585 0.168 0.139 0.200 0.000 1.42 Low 2001 North America
Mafi 2013 227 / 831 0.273 0.244 0.304 0.000 1.48 Moderate 2003 North America
Mafi  2015 134 / 577 0.232 0.200 0.268 0.000 1.45 Low 2003 North America
Rolita 2013 61 / 3731 0.016 0.013 0.021 0.000 1.39 Moderate 2003 North America
Wright 2013 151 / 488 0.309 0.270 0.352 0.000 1.45 High 2003 North America
Richter 2017 60 / 244 0.246 0.196 0.304 0.000 1.35 Moderate 2004 North America
Ashworth 2013 234 / 715 0.327 0.294 0.363 0.000 1.48 Low 2005 Europe
Carbone 2013 5106 / 7447 0.686 0.675 0.696 0.000 1.53 Moderate 2005 North America
Mafi 2013 245 / 816 0.300 0.270 0.333 0.000 1.48 Moderate 2005 North America
Mafi  2015 86 / 504 0.171 0.140 0.206 0.000 1.41 Low 2005 North America
Richter 2017 67 / 244 0.275 0.222 0.334 0.000 1.36 Moderate 2005 North America
Beehler 2013 524 / 792 0.662 0.628 0.694 0.000 1.48 Moderate 2006 North America
Berger 2012 15444 / 31688 0.487 0.482 0.493 0.000 1.53 Moderate 2006 Europe
Podichetty 2008 283 / 486 0.582 0.538 0.625 0.000 1.46 Moderate 2006 North America
Richter 2017 67 / 244 0.275 0.222 0.334 0.000 1.36 Moderate 2006 North America
Wright 2013 186 / 477 0.390 0.347 0.434 0.000 1.45 High 2006 North America
Fredheim  2014 2204 / 14477 0.152 0.146 0.158 0.000 1.53 Low 2007 Europe
Mafi 2013 508 / 979 0.519 0.488 0.550 0.237 1.50 Moderate 2007 North America
Mafi  2015 101 / 522 0.193 0.162 0.230 0.000 1.42 Low 2007 North America
Mohanty 2016 2419 / 8208 0.295 0.285 0.305 0.000 1.53 Moderate 2007 North America
Richter 2017 68 / 244 0.279 0.226 0.338 0.000 1.36 Moderate 2007 North America
Rolita 2013 3329 / 11012 0.302 0.294 0.311 0.000 1.53 Moderate 2007 North America
Sule 2008 17 / 467 0.036 0.023 0.058 0.000 1.11 High 2007 South East Asia
Vincent 2015 423 / 1111 0.381 0.353 0.410 0.000 1.50 Moderate 2007 North America
Dobscha 2013 2040 / 5961 0.342 0.330 0.354 0.000 1.53 Low 2008 North America
Fitzcharles 2011 144 / 457 0.315 0.274 0.359 0.000 1.44 Moderate 2008 North America
Henderson 2013 356 / 1088 0.327 0.300 0.356 0.000 1.50 Low 2008 Western Pacific
Richter 2017 71 / 244 0.291 0.237 0.351 0.000 1.36 Moderate 2008 North America
Shadd 2015 543 / 1219 0.445 0.418 0.473 0.000 1.50 Moderate 2008 North America
Wilson 2015 76495 / 238536 0.321 0.319 0.323 0.000 1.53 Moderate 2008 Europe
Edlund 2014 662090 / 1332810 0.497 0.496 0.498 0.000 1.54 Low 2009 North America
Mafi 2013 295 / 700 0.421 0.385 0.458 0.000 1.48 Moderate 2009 North America
Mafi 2015 93 / 594 0.157 0.130 0.188 0.000 1.42 Low 2009 North America
Richter 2017 73 / 244 0.299 0.245 0.360 0.000 1.37 Moderate 2009 North America
Robinson 2012 672 / 1700 0.395 0.372 0.419 0.000 1.51 Moderate 2009 North America
Steinman 2015 597 / 6559 0.091 0.084 0.098 0.000 1.52 Moderate 2009 North America
Wright  2013 168 / 422 0.398 0.352 0.446 0.000 1.44 High 2009 North America
Zamora-Legoff  2016 155 / 501 0.309 0.270 0.351 0.000 1.45 Moderate 2009 North America
Curtis 2017 97859 / 240750 0.406 0.405 0.408 0.000 1.53 Moderate 2010 North America
Edlund 2014 700140 / 1405563 0.498 0.497 0.499 0.000 1.54 Low 2010 North America
Margolis 2016 28368 / 64038 0.443 0.439 0.447 0.000 1.53 Moderate 2010 North America
Park 2016 4707 / 12165 0.387 0.378 0.396 0.000 1.53 Low 2010 North America
Richter 2017 73 / 244 0.299 0.245 0.360 0.000 1.37 Moderate 2010 North America
Young 2011 210 / 360 0.583 0.532 0.633 0.002 1.43 High 2010 North America
Birtwhistle 2015 9761 / 29562 0.330 0.325 0.336 0.000 1.53 Low 2011 North America
Edlund 2014 720287 / 1437392 0.501 0.500 0.502 0.008 1.54 Low 2011 North America
Perez 2013 4847 / 8579 0.565 0.554 0.575 0.000 1.53 Moderate 2011 Europe
Richter 2017 73 / 244 0.299 0.245 0.360 0.000 1.37 Moderate 2011 North America
Tian 2013 3231 / 7491 0.431 0.420 0.443 0.000 1.53 Low 2011 North America
Richter 2017 72 / 244 0.295 0.241 0.355 0.000 1.36 Moderate 2012 North America
Romanelli 2017 69935 / 120481 0.580 0.578 0.583 0.000 1.53 Low 2012 North America
Videla 2017 126 / 269 0.468 0.409 0.528 0.300 1.40 Moderate 2012 Europe
Richter 2017 65 / 244 0.266 0.215 0.325 0.000 1.35 Moderate 2013 North America
Richter 2017 68 / 244 0.279 0.226 0.338 0.000 1.36 Moderate 2014 North America
Richter 2017 75 / 244 0.307 0.253 0.368 0.000 1.37 Moderate 2015 North America
0.307 0.287 0.327 0.000
0.00 0.50 1.00



















Figure 3: Adjusted estimates of opioid analgesics prescribed over time.  
Meta-regression model was calculated in logit space, adjusted for WHO region, the disclosure 
of funding, setting, duration of the sampling period and year of study sampling. Adjusted 
estimates for each study were back transformed from logit scale to percentages and presented 
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Data source Number of 
participants 
Diagnosis 
Almakadma 2013 UK 1990-2006 Tertiary Retrospective cross-sectional review 
of medical records 
1,500 Chronic pain 
Ashworth 2013 UK 2004-2006 Primary Prospective cohort questionnaire 715 Chronic low back 
pain 
Beehler 2013 USA 2003-2009 Primary, secondary 
(specialist) 





Berger 2012 UK 2006 Primary Retrospective cohort record review 
(The Health Improvement Network) 
31,688 Painful neuropathic 
disorders 
Birtwhistle 2015 Canada 2010-2012 Primary Retrospective cohort review of 
medical records (Canadian Primary 
Care Sentinel Surveillance Network) 
29,562 Osteoarthritis and 
spondylosis 
Carbone 2013 USA 2002-2007 Population-based (Veterans 
Affairs database) 
Retrospective review of Veterans 
Affairs Healthcare System records 
7447 Chronic pain and 
spinal cord injury 
Castillo 2006 USA 1994-1997 Tertiary  Prospective cohort from Lower 
Extremity Assessment Project 
569 Chronic pain post 
fracture 
Clarke 2002 USA 2000 Population-based (Veterans 
Affairs database) 
Retrospective cross-sectional review 




Cowan 2003 UK 1999-2009 Tertiary Retrospective cross-sectional review 
of medical records 
1,393 Chronic pain 




Dobscha 2013 USA 2008 Population-based (Veterans 
Affairs database)  
Prospective case control review 
(Veterans Integrated Service 
Network) 
17,126 Chronic pain 
Dominick 2004 USA 1998-1999 Population-based (Veterans 
Affairs database) 
Retrospective cohort review of 
medical records (Durham Veterans 
Affairs Medical Centre) 
3 061 Osteoarthritis 
Edlund 2014 USA 2009-2011 Population-based (Veterans 
Affairs database) 





Fitzcharles 2011 Canada 2005-2010 Tertiary Retrospective cross-sectional review 
of medical records 
457 Fibromyalgia 
Fredheim 2014 Norway 2006-2008 Population-based 
(dispensing database) 
Cross sectional random sample of 3 
surveys/databases 
14,477 Chronic pain 
Gore 2007 USA 2001 Primary Retrospective cross-sectional 







(General Practice Research 
Database) 
Henderson 2013 Australia 2008-2009 Primary Retrospective cross-sectional 
survey (Bettering the Evaluation And 
Care of Health program) 
1,113 Chronic pain 
Jensen 2006 Denmark 1989-1992 Tertiary Retrospective cross-sectional review 
of medical records 
160 Chronic pain 
Mafi 2013 USA 1999-2010 Secondary (outpatient, ED) Retrospective cohort database of 
medical records (NAMCS and 
NHAMCS) 
4,623 Chronic low back 
and neck pain 
Mafi 2015 USA 1999-2010 Secondary (outpatient) Retrospective cohort database of 
medical records (NAMCS and 
NHAMCS) 
3134 Chronic headache 
Mahowald 2005 USA 1997 Secondary (specialist) Retrospective cohort of medical 
records (Spine Clinic of the 
Minneapolis Veterans Affairs 
Medical Center) 
230 Chronic low back 
pain 
Mapel 2004 USA 2000-2001 Population-based (claims 
database) 
Retrospective cohort database of 
medical records (Lovelace Health 
Plan) 
8,993 Chronic low back 
pain, osteoarthritis 
Margolis 2016 USA 2008-2012 Population-based (private 
data company) 
Retrospective cross-sectional 
database of medical records 
(Humedica) 
64,038 Fibromyalgia 
Mohanty 2016 USA 2002-2012 Population-based (Veterans 
Affairs database) 
Retrospective cross-sectional 
medical chart review of veterans 
8,208 Fibromyalgia 
Park 2016 USA 2010 Population-based (claims 
database) 
Retrospective cross-sectional review 
of medical records (Henry Ford 
Health System) 
12,165 Chronic pain 
Perez 2013 Spain 2011 Primary, secondary 
(specialist) 
Retrospective cross-sectional review 
of medical records 
8,695 Chronic pain 
Podichetty 2008 USA 2005-2007 Tertiary Prospective cohort 486 Chronic low back 
pain 
Ritcher 2017 USA 2005-2015 Secondary (outpatient), 
tertiary 
Retrospective cohort of medical 




Robinson 2012 USA 2008-2010 Primary, secondary 
(specialist) 





Rolita 2013 USA 2001-2009 Population-based (claims 
database) 
Retrospective case-control of 
medical records (Geisinger Health 
System) 
13,354 Osteoarthritis 




Sutter Health electronic health 
record data 
120,481 Chronic pain 
Shadd 2015 Canada 2005-2010 Primary Retrospective cohort of medical 
records (Deliver Primary Healthcare 
Information) 
1219 Neuropathic pain 
Steinman 2015 USA 1999-2010 Secondary (outpatient) Retrospective cohort database of 
medical records (NAMCS and 
NHAMCS) 
6,559 Chronic pain 
Sule 2008 India NR Secondary (specialist) Prospective cohort 467 Neuropathic pain 
Tian 2013 USA 2011-2012 Primary Retrospective cohort of medical 
records (eClinicalWorks) 
7,491 Chronic pain 
Turk 1997 USA NR Tertiary Prospective cohort 191 Chronic pain 
Videla 2017 Spain 2011-2014 Secondary (specialist) Prospective cohort 269 Chronic pain 
Vincent 2015 USA 2005-2009 Secondary, tertiary  Retrospective cohort of medical 
records (Rochester Epidemiology 
Project) 
1,111 Fibromyalgia 
Wilson 2013 Spain 2006 Primary Retrospective review medical 
records (Sistema d‘Informacio´ per 
al Desenvolupament de 
l‘Investigacio´ en Atencio´ Prima` ria 
(SIDIAP) database) 
238,536 Osteoarthritis 




Retrospective cross-sectional review 
from claims database (MCBS & 
Medicare) 
1,387 Knee osteoarthritis 




USA 2005-2014 Secondary outpatient), 
tertiary  
Retrospective cohort of medical 




Table 1: Description of included studies.   
Abbreviations: NR = Not Reported; ED = Emergency Department; NAMCS = The National Ambulatory Medical Care Survey; NHAMCS = 
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Appendix 1: Search strategies 
 PubMed (NLM® database) 
(epidemiologic studies OR cohort studies OR cross sectional studies OR (epidemiologic adj (study or 
studies)) OR (follow up adj (study or studies)) OR retrospective* OR longitudinal OR prospective* OR 
(observ* adj (study or studies))) AND (prevalence OR occurrence OR burden) AND ((chronic pain) 
OR (chronic non-cancer pain or chronic non cancer pain or chronic noncancer pain) OR (chronic non-
malignant pain or chronic non malignant pain or chronic nonmalignant pain) OR (pain adj (long-term 
or long term or longterm or persistent)) OR human) AND (NO2A* OR (opioid* adj3 analges*) OR 
opioid* OR (opioid* adj3 medicine) OR (opioid* adj3 drug*) OR narcotic*  OR (narcotic* adj3 drug*)  
OR (narcotic* adj3 analges*)  OR morphine OR ordine  OR hydromorphone  OR dilaudid OR 
oxycodone  OR endone  OR targin  OR oxymorphone  OR OPANA*  OR codeine  OR dihydrocodeine  
OR (opioid* adj3 alkaloid*)  OR ketobemidone  OR (phenylpiperidine adj3 deriv*)  OR pethidine  OR 
fentanyl  OR durogesic  OR diphenylpropylamine  OR dextromoramide  OR piritramide  OR 
dextropropoxyphene  OR di-gesic  OR capodex  OR bezitramide  OR methadone  OR physeptone  
OR (benzomorphan adj3 deriv*)  OR pentazocine  OR phenazocine  OR (oripavine adj3 deriv*)  OR 
buprenorphine  OR norspan  OR suboxone  OR subutex  OR etorphine  OR (morphinan adj3 deriv*)  
OR tilidine  OR trama*  or tramadol  OR dezocine  OR tapendatol  OR meptazinol  OR nicomorphine  
OR butorphanol OR nalbuphine)) 
  
MEDLINE, EMBASE and International Pharmaceutical Abstracts (OvidSP)  
((epidemiologic studies or cohort studies or cross sectional studies or (epidemiologic adj (study or 
studies)) or (follow up adj (study or studies)) or retrospective* or prospective* or (observ* adj (study or 
studies))) and (prevalence or occurrence or burden) and ((chronic pain) or (chronic non-cancer pain 
or chronic non cancer pain or chronic noncancer pain) or (chronic non-malignant pain or chronic non 
malignant pain or chronic nonmalignant pain) or (pain adj (long-term or long term or longterm or 
persistent)) or human) and (NO2A* or (opioid* adj25 analges*) or opioid* or (opioid* adj25 med*) or 
(opioid* adj25 drug*) or narcotic* or (narcotic* adj25 drug*) or (narcotic* adj25 analges*) or morphine 
or (morphine adj25 sul*) or ordine or hydromorphone or dilaudid or oxy* or oxycodone or endone or 
targin or oxymorphone or OPANA* or codeine or dihydrocodeine or (opi* adj25 alkaloid*) or 
ketobemidone or (phenylpiperidine adj25 deriv*) or pethidine or fentanyl or durogesic or 
diphenylpropylamine or dextromoramide or piritramide or dextropropoxyphene or di-gesic or capodex 
or bezitramide or methadone or physeptone or (benzomorphan adj25 deriv*) or pentazocine or 
phenazocine or (oripavine adj25 deriv*) or buprenorphine or norspan or suboxone or subutex or 
etorphine or (morphinan adj25 deriv*) or tilidine or trama* or tramadol or dezocine or tapendatol or 
meptazinol or nicomorphine or butorphanol or nalbuphine)) 
  
Web of Science (Thomson Reuters)  
((((((((((((((epidemiologic studies OR cohort studies) OR cross sectional studies) OR (epidemiologic 
NEAR study)) OR (epidemiologic NEAR studies)) OR (follow up NEAR study)) OR (follow up NEAR 
studies)) OR retrospective$) OR prospective$) OR (observ$ NEAR study)) OR (observ$ NEAR 
studies))) AND ((prevalence OR occurrence) OR burden)) AND ((((chronic pain OR ((chronic non-
cancer pain OR chronic non cancer pain) OR chronic noncancer pain)) OR ((chronic non-malignant 
pain OR chronic non malignant pain) OR chronic nonmalignant pain)) OR ((((pain NEAR long-term) 
OR (pain NEAR long term)) OR (pain NEAR longerterm)) OR (pain NEAR persistent))) OR human)) 
AND ((((((((((((((((((((((((((((((((((((((((((((((((((((NO2A$ OR opioid$ ada3 analges$) OR opioid$) OR 
opioid$ ada3 medicine) OR opioid$ ada3 drug$) OR narcotic$) OR narcotic$ ada3 drug$) OR 
narcotic$ ada3 analges$) OR morphine) OR ondine) OR hydromorphone) OR diclaudio) OR 
oxycodone) OR enzone) OR targis) OR oxymorphone) OR OPANA$) OR codeine) OR 
dihydrocodeine) OR opioid$ ada3 alkaloid$) OR ketobemidon) OR phenylpiperidino ada3 deriv$) OR 
pethidine) OR fentanyl) OR duragesic) OR diphenylpropylamino) OR dextromoramide) OR piritramid) 
OR dextropropoxyphene) OR di-gesic) OR casodex) OR bezitramide) OR methadone) OR physetine) 
OR benzomorphans ada3 deriv$) OR pentazocine) OR pentazocine) OR oripavines ada3 deriv$) OR 
buprenorphine) OR norstar) OR subclone) OR suratex) OR exorphins) OR morphinans ada3 deriv$) 
OR tolidine) OR trama$) OR tramadol) OR diazocine) OR tapentadol) OR meptazinol) OR 
nicomorphine) OR butorphanol) OR nalbuphine))  
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Appendix 2: Opioid classification and conversion 
  
N02A Opioids Category 
N02AA Natural opium alkaloids  
N02AA01 Morphine Strong 
N02AA02 Opium Strong 
N02AA03 Hydromorphone Strong 
N02AA04 Nicomorphine Strong 
N02AA05 Oxycodone Strong 
N02AA08 Dihydrocodeine Weak 
N02AA10 Papaveretum Strong  
N02AA51 Morphine, combinations Strong 
N02AA55 Oxycodone and naloxone Strong 
N02AA58 Dihydrocodeine, combinations Combination – weak 
N02AA59 Codeine, combinations excluding psycholeptics Combination – weak 
N02AA79 Codeine, combinations with psycholeptics Combination – weak 
N02AB Phenylpiperidine derivatives  
N02AB01 Ketobemidone Strong 
N02AB02 Pethidine Strong 
N02AB03 Fentanyl Strong 
N02AB52 Pethidine, combinations excluding psycholeptics Combination – strong 
QN02AB53 Fentanyl, combinations excluding psycholeptics Combination – strong 
N02AB72 Pethidine, combinations with psycholeptics Combination – strong 
QN02AB73 Fentanyl, combinations with psycholeptics Combination – strong 
N02AC Diphenylpropylamine derivatives  
N02AC01 Dextromoramide Strong 
N02AC03 Piritramide Strong  
N02AC04 Dextropropoxyphene Weak 
N02AC05 Bezitramide Strong 
N02AC52 Methadone, combinations excluding psycholeptics Combination – strong 
N02AC54 Dextropropoxyphene, combinations excluding psycholeptics Combination – weak 
N02AC74 Dextropropoxyphene, combinations with psycholeptics Combination – strong 
N02AD Benzomorphan derivatives  
N02AD01 Pentazocine Strong 
N02AD02 Phenazocine Strong 
N02AE Oripavine derivatives  
N02AE01 Buprenorphine Strong 
N02AF Morphinan derivatives  
N02AF01 Butorphanol Strong 
N02AF02 Nalbuphine Strong 
N02AG Opioids in combination with antispasmodics  
N02AG01 Morphine and antispasmodics Combination – strong 
N02AG02 Ketobemidone and antispasmodics Combination – strong 
N02AG03 Pethidine and antispasmodics Combination – strong 
N02AG04 Hydromorphone and antispasmodics Combination – strong 
N02AJ Opioids in combination with non-opioid analgesics  
N02AJ01 Dihydrocodeine and paracetamol (acetaminophen) Combination – weak 
N02AJ02 Dihydrocodeine and acetylsalicylic acid Combination – weak  
N02AJ03 Dihydrocodeine and other non-opioid analgesics Combination – weak 
N02AJ06 Codeine and paracetamol (acetaminophen) Combination – weak 
N02AJ07 Codeine and acetylsalicylic acid Combination – weak 
N02AJ08 Codeine and ibuprofen Combination – weak 
N02AJ09 Codeine and other non-opioid analgesics Combination – weak 
N02AJ13 Tramadol and paracetamol (acetaminophen) Combination – weak 
N02AJ14 Tramadol and dexketoprofen Combination – weak 
N02AJ15 Tramadol and other non-opioid analgesics Combination – weak 
N02AJ17 Oxycodone and paracetamol (acetaminophen) Combination – strong 
N02AJ18 Oxycodone and acetylsalicylic acid Combination – strong 
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N02AJ19 Oxycodone and ibuprofen Combination – strong 
N02AX Other opioids  
N02AX01 Tilidine Weak 
N02AX02 Tramadol Weak 
N02AX03 Dezocine Strong 
N02AX05 Meptazinol Strong 
N02AX06 Tapentadol Strong 
  
Morphine milligram equivalents (MME) was calculated as per Dowell et al. 
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Appendix 3: Risk of bias scores and assessment criteria 
 














































AlMakadma 2013 High Low High High High High High Low High Low High 
Ashworth 2013 High High Low Low Low Low Low Low Low Low Low 
Beehler 2013 High Low Low Low Low High High Low Low Low Moderate 
Berger 2012 Low High Low High Low High High Low Low Low Moderate 
Birtwhistle 2015 Low High Low Low Low High Low Low Low Low Low 
Carbone 2013 Low High High High High Low Low High High High Moderate 
Castillo 2016 High High High High Low Low High Low Low Low Moderate 
Clarke 2002 High Low Low Low Low High High Low Low High Moderate 
Cowan 2003 High Low Low Low Low High High Low Low Low Moderate 
Curtis 2017 Low High Low High Low Low High Low Low Low Moderate 
Dobscha 2013 High Low Low Low Low Low High Low Low Low Low 
Dominick 2004 High High High High Low High High Low Low Low High 
Edlund 2014 Low Low Low Low Low High High Low Low Low Low 
Fitzcharles 2011 High High Low Low Low High High Low Low Low Moderate 
Fredheim 2014 Low Low Low High Low Low High Low Low Low Low 
Gore 2007 Low High High Low Low High Low Low Low Low Moderate 
Henderson 2013 High Low Low Low Low Low Low Low Low Low Low 
Jensen 2006 High Low Low Low Low High High Low High Low Moderate 
Mafi 2013 Low High Low Low Low High High Low Low Low Moderate 
Mafi 2015 Low High Low Low Low Low High Low Low Low Low 
Mahowald High High Low Low Low High High Low Low Low Moderate 
Mapel 2004 Low High Low Low Low High Low Low Low Low Low 
Margolis 2004 Low High Low Low Low High High Low Low Low Moderate 
Mohanty 2016 Low High Low Low Low High High Low Low Low Moderate 
Park 2016 Low Low Low Low Low High High Low Low Low Low 
Perez 2013 High Low High High Low Low High Low Low Low Moderate 
Podichetty 2008 High High Low High Low Low High Low High Low Moderate 
Richter 2017 Low High Low Low Low High High Low Low Low Moderate 
Robinson 2012 High High High Low Low Low High Low Low Low Moderate 
Rolita 2013 Low High Low Low Low High High Low Low Low Moderate 
Romanelli 2017 Low Low Low Low Low High High Low Low Low Low 
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Shadd 2015 High High Low Low Low High High Low Low Low Moderate 
Steinman 2015 Low High Low Low Low High High Low Low Low Moderate 
Sule 2008 High High High High Low Low High Low Low High High 
Tian 2013  High Low Low Low Low Low High Low Low Low Low 
Turk 1997 High Low Low Low Low High High Low Low Low Moderate 
Videla 2017 High Low High High Low High High Low Low Low Moderate 
Vincent 2015 High High Low Low Low High High Low Low Low Moderate 
Wilson 2015 High Low High High High Low Low High High High Moderate 
Wright 2013 High High High High Low High High Low Low Low High 
Young 2011 High High High High Low Low High Low Low Low High 
Zamora-Legoff 2016 High High Low Low Low High High Low Low Low Moderate 
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Risk of bias questions modified from Hoy et al 2012. 
  
 
Assessment  Additional notes and examples# 
External validity   
1.  Was the study’s target population a close representation of the national population in 
relation to relevant variables, e.g. age, sex, occupation? 
• Yes (LOW RISK): The study’s target 
population was a close 
representation of the national 
population. 
• No (HIGH RISK): The study’s target 
population was clearly NOT 
representative of the national 
population.  
 
The target population refers to the group of people with 
chronic pain or entities to which the results of the study 
will be generalized. Examples: 
• The study was a national health survey of people 15 
years and over and the sample was drawn from a list 
that included all individuals in the population aged 15 
years and over. The answer is: Yes (LOW RISK). 
• The study was conducted in one province or village or 
one clinic only, and it is not clear if this was 
representative of the national population. The answer 
is: No (HIGH RISK). 
2. Was the sampling frame a true or close representation of the target population? 
• Yes (LOW RISK): The sampling 
frame was a true or close 
representation of the target 
population. 
• No (HIGH RISK): The sampling 
frame was NOT a true or close 
representation of the target 
population. 
 
The sampling frame is a list of the sampling units in the 
target population and the study sample is drawn from 
this list. Examples: 
• The sampling frame was a list of almost every 
individual within the target population (i.e. all types of 
chronic pain). The answer is: Yes (LOW RISK). 
• The cluster sampling method was used and the 
sample of clusters/villages was drawn from a list of all 
villages in the target population. The answer is: Yes 
(LOW RISK). 
• The sampling frame was a list of just one particular 
ethnic group within the overall target population, or 
city, which comprised many groups (i.e. only a 
subgroup of chronic pain patients i.e. chronic back 
pain only). The answer is: No (HIGH RISK). 
3. Was some form of random selection used to select the sample, OR, was a census 
undertaken? 
• Yes (LOW RISK): A census was 
undertaken, OR, some form of 
random selection was used to select 
the sample (e.g. simple random 
sampling, stratified random 
sampling, cluster sampling, 
systematic sampling). 
• No (HIGH RISK): A census was NOT 
undertaken, AND some form of 
random selection was NOT used to 
select the sample. 
A census collects information from every unit in the 
sampling frame. In a survey, only part of the sampling 
frame is sampled. In these instances, random selection 
of the sample helps minimize study bias. Examples: 
• The sample was selected using simple random 
sampling. The answer is: Yes (LOW RISK). 
• The target population was the village and every 
person in the village was sampled. The answer is: Yes 
(LOW RISK). 
• The nearest villages to the capital city were selected in 
order to  save on the cost of fuel. The answer is: No 
(HIGH RISK). 
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4. Was the likelihood of non-response bias minimal? 
• Yes (LOW RISK): The response rate 
for the study was ≥ 75%, OR, an 
analysis was performed that showed 
no significant difference in relevant 
demographic characteristics 
between responders and non- 
responders, or entire database. 
• No (HIGH RISK): The response rate 
was <75%, and if any analysis 
comparing responders and non-
responders was done, it showed a 
significant difference in relevant 
demographic characteristics 
between responders and non-
responders. 
Examples: 
• The response rate was 68%; however, the 
researchers did an analysis and found no significant 
difference between responders and non-responders in 
terms of age, sex, occupation and socioeconomic 
status. The answer is: Yes (LOW RISK). 
• The response rate was 65% and the researchers did 
NOT carry out an analysis to compare relevant 
demographic characteristics between responders and 
non-responders. The answer is: No (HIGH RISK). 
• The response rate was 69% and the researchers did 
an analysis and found a significant difference in age, 
sex and socio-economic status between responders 
and non-responders. The answer is: No (HIGH RISK). 
 Internal validity   
5. Were data collected directly from the subjects (as opposed to a proxy)? 
• Yes (LOW RISK): All data were 
collected directly from the subjects. 
• No (HIGH RISK): In some instances, 
data were collected from a proxy. 
A proxy is a representative of the subject. Examples: 
• All eligible subjects in the household were 
interviewed separately. The answer is: Yes (LOW 
RISK). 
• A representative of the household was interviewed 
and questioned about the presence of low back pain 
in each household member. The answer is: No 
(HIGH RISK). 
6. Was an acceptable case definition used in the study? 
• Yes (LOW RISK): An acceptable 
case definition was used. Duration of 
chronic pain must be stated and 
followed appropriate 
standard/guideline. 
• No (HIGH RISK): An acceptable 
case definition was NOT used. 
Example: 
• For a study on low back pain, the following case 
definition was used: “Low back pain is defined as 
activity-limiting pain lasting more than one day in the 
area on the posterior aspect of the body from the 
bottom of the 12th rib to the lower gluteal folds”. The 
answer is: Yes (LOW RISK). 
• For a study on back pain, there was no description of 
the specific anatomical location “back‟ referred to. 
The answer is: No (HIGH RISK). 
• For a study on osteoarthritis, the following case 
definition was used: “Symptomatic osteoarthritis of 
the hip or knee, radiologically confirmed as Kellgren-
Lawrence grade 2-4”. The answer is: Yes (LOW 
RISK). 
7. Was the study instrument that measured the parameter of interest (e.g. prevalence of low 
back pain) shown to have reliability and validity (if necessary)? 
• Yes (LOW RISK): The study 
instrument had been shown to have 
reliability and validity (if this was 
necessary), e.g. test-re- test, piloting, 
validation in a previous study, etc. 
Example: 
• The authors used a questionnaire which had 
previously been validated. They also tested the inter-
rater reliability of the questionnaire. The answer is: 
Yes (LOW RISK). 
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• No (HIGH RISK): The study 
instrument had NOT been shown to 
have reliability or validity (if this was 
necessary). 
• The authors developed their own questionnaire (or 
medical chart review) and did not test this for validity 
or reliability. The answer is: No (HIGH RISK).  
8. Was the same mode of data collection used for all subjects? 
• Yes (LOW RISK): The same mode of 
data collection was used for all 
subjects. 
• No (HIGH RISK): The same mode of 
data collection was NOT used for all 
subjects. 
The mode of data collection is the method used for 
collecting information from the subjects. The most 
common modes are face-to-face interviews, telephone 
interviews and self-administered questionnaires. 
Examples: 
• All eligible subjects had a face-to-face interview. The 
answer is: Yes (LOW RISK). 
• Some subjects were interviewed over the telephone 
and some filled in postal questionnaires. The answer 
is: No (HIGH RISK). 
9. Was the length of the shortest prevalence period for the parameter of interest 
appropriate? 
• Yes (LOW RISK): The shortest 
prevalence period for the parameter 
of interest was appropriate (e.g. 
point prevalence). 
• No (HIGH RISK): The shortest 
prevalence period for the parameter 
of interest was not appropriate (e.g. 
lifetime prevalence) 
The prevalence period is the period that the subject is 
asked about e.g. “Have you experienced low back pain 
over the previous year?” In this example, the prevalence 
period is one year. The longer the prevalence period, the 
greater the likelihood of the subject forgetting if they 
experienced the symptom of interest (e.g. low back 
pain). Examples: 
• Subjects were asked about medicine use over the 
past week or no recall bias likely (i.e. medical chart 
review). The answer is: Yes (LOW RISK). 
• Subjects were asked about medicine use for the last 
month or longer (i.e. subjective recall with no 
objective measure). The answer is: No (HIGH RISK). 
10.   Were the numerator(s) and denominator(s) for the parameter of interest appropriate? 
• Yes (LOW RISK): The paper 
presented appropriate numerator(s) 
AND denominator(s) for the 
parameter of interest (e.g. the 
prevalence of low back pain). 
• No (HIGH RISK): The paper did 
present numerator(s) AND 
denominator(s) for the parameter of 
interest but one or more of these 
were inappropriate. 
There may be errors in the calculation and/or reporting 
of the numerator and/or denominator. Examples: 
• There were no errors in the reporting of the 
numerator(s) AND denominator(s) for the prevalence 
of low back pain. The answer is: Yes (LOW RISK). 
• In reporting the overall prevalence of low back pain 
(in both men and women), the authors accidentally 
used the population of women as the denominator 
rather than the combined population. The answer is: 
No (HIGH RISK). 
# If there is insufficient information = No (HIGH RISK) for that particular item. 
 
 
A study’s overall risk of bias was considered: 
• ‘Low’ if further research was very unlikely to change our confidence in the estimate;  
• ‘Moderate’ if further research was likely to have an important impact on our 
confidence in the estimate and may change the estimate; or  
• ‘High’ if further research was very likely to have an important impact on our 
confidence in the estimate and was likely to change the estimate. 
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Appendix 4: GRADE criteria and scoring 
  
The overall quality of evidence may be: 
• High: further research is very unlikely to change the confidence in the estimate of effect.  
• Moderate: further research is likely to have an important impact in the confidence in the 
estimate of effect and may change the estimate. 
• Low: further research is very likely to have an important impact on our confidence in the 
estimate of effect and is likely to change the estimate.  
• Very Low: any estimate of effect is very uncertain.  
  
 
Reasons for downgrade: 
Each domain were assessed, and points downgraded or upgraded accordingly from “high” quality 
evidence. 
  
Factors that downgrade the quality of evidence: 
1. Limitations in the design and implementation of available studies suggesting high likelihood of 
bias. 
2. Indirectness of evidence (indirect population, intervention, control, outcomes). 
3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup 
analyses). 
4. Imprecision of results (wide confidence intervals). 




Assessment criteria  
Domain Assessment criteria 
1. Study design No randomised controlled trials were included in this review. We did not 
downgrade for studies being observational in design as this the appropriate 
method of measuring prevalence. Only observational studies containing a 
representative sample were included in this review. This included 
representativeness from the population which participants were sampled, 
participants were representative of the disease/condition of interest etc.  
2. Risk of bias Risk was bias was assessed using the criteria by Hoy et al. 
No downgrade given if all studies had “low” overall risk of bias score. 
Downgrade by one level if an overall risk of bias score of “moderate” or “high” 
was found across studies. 
3. Inconsistency Statistical heterogeneity was considered present if the I2 value suggested 
substantial heterogeneity was present and there were widely differing 
estimates of effect. Clinical heterogeneity was considered in the domain of 
indirectness. 
No downgrade given if no statistical heterogeneity was present or only one 
study was present. 
Downgraded by one level if statistical heterogeneity was present. 
4. Indirectness Indirectness refers to how well the evidence included in the review answers 
the review question. Indirectness may come from indirect: 
• Population: mean age, gender bias, ethnicity, pain mechanism. 
• Intervention: opioid dosing. 
• Comparator: not applicable 
• Outcome: missing data 
 
No downgrade if indirectness was not present. 
Downgraded by one level if indirectness was present in either population, 
intervention or outcomes. 
5. Imprecision Results are imprecise there is variation in the effect. 
No downgrade if there were narrow confidence intervals around the 
prescribing estimate. 




Publication bias is a systematic under or over estimation of the underlying 
effect, due to the selective publication of studies or availability of their data. 
We did not assess publication bias because of uncertainty in assessing for 
missing observational studies and applying funnel plots for observational 
studies is not well established. 
  
  












Inconsistency Indirectness Imprecision Publication 
bias 
Overall score 
Chronic non-cancer pain        
All opioids 0 -1 0# 0 0 NA Moderate 
Weak opioids 0 -1 -1 (I2 = 72.3%) 0 0 NA Low 
Strong opioids 0 -1 -1 (I2 = 84.3%) 0 0 NA Low 
Weak combination opioids 0 -1 0 (I2 = 0%) 0 0 NA Moderate 
Strong combination opioids 0 -1 0 (I2 = 0%) 0 -1 NA Low 
Chronic low back pain        
All opioids 0 -1 0# 0 -1 NA Low 
Weak opioids 0 -1 0 (I2 = 0%) 0 0 NA Moderate 
Strong opioids       NA 
Weak combination opioids       NA 
Strong combination opioids       NA 
# Statistical heterogeneity was explored in meta-regression. 
Abbreviations: NA = no subgroup analysis conducted.
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Appendix 5: Forest plots 
 






Statistics for each study
Event Lower  Upper  Relative 
Total Total rate limit lim it p-Value weight
Stron Jensen 2006 Strong 1991 64 160 0.400 0.327 0.478 0.012 4.02
Stron Mahowald 2005 Strong 1997 56 230 0.243 0.192 0.303 0.000 4.08
Stron Cowan 2003 Strong 1999 341 1393 0.245 0.223 0.268 0.000 4.61
Stron Dominick 2004 Strong 1999 54 3061 0.018 0.014 0.023 0.000 4.20
Stron Clarke 2002 Strong 2000 27 143 0.189 0.133 0.261 0.000 3.61
Stron Gore 2007 Strong 2001 3464 30999 0.112 0.108 0.115 0.000 4.73
Stron Carbone 2013 Strong 2005 5907 7447 0.793 0.784 0.802 0.000 4.71
Stron Curtis 2017 Strong 2007 34740 240750 0.144 0.143 0.146 0.000 4.73
Stron Dobscha 2013 Strong 2008 2040 5961 0.342 0.330 0.354 0.000 4.71
Stron Fitzcharles 2011 Strong 2008 105 457 0.230 0.193 0.271 0.000 4.37
Stron Henderson 2013 Strong 2008 160 1088 0.147 0.127 0.169 0.000 4.51
Stron Wilson 2015 Strong 2008 9822 238536 0.041 0.040 0.042 0.000 4.73
Stron Zamora-Legoff 2016 Strong 2008 112 501 0.224 0.189 0.262 0.000 4.39
Stron Curtis 20178 Strong 2008 35719 240750 0.148 0.147 0.150 0.000 4.73
Stron Curtis 2017 Strong 2009 37676 240750 0.156 0.155 0.158 0.000 4.73
Stron Curtis 2017 Strong 2010 39633 240750 0.165 0.163 0.166 0.000 4.73
Stron Curtis 2017 Strong 2011 41101 240750 0.171 0.169 0.172 0.000 4.73
Stron Birtwhistle 2015 Strong 2011 3898 29562 0.132 0.128 0.136 0.000 4.73
Stron Perez 2013 Strong 2011 2564 8695 0.295 0.285 0.305 0.000 4.72
Stron Curtis 2017 Strong 2012 41590 240750 0.173 0.171 0.174 0.000 4.73
Stron Curtis 2017 Strong 2013 41101 240750 0.171 0.169 0.172 0.000 4.73
Stron Curtis 2017 Strong 2014 40122 240750 0.167 0.165 0.168 0.000 4.73
Stron 0.184 0.160 0.210 0.000
Stron Dominick 2004 Strong combination 1999 1176 3061 0.384 0.367 0.402 0.000 49.99
Stron Perez 2013 Strong combination 2011 1210 8695 0.139 0.132 0.147 0.000 50.01
Stron 0.241 0.078 0.544 0.089
Wea Jensen 2006 Weak 1991 0 160 0.003 0.000 0.048 0.000 0.36
Wea Mahowald 2005 Weak 1997 109 230 0.474 0.410 0.539 0.429 3.77
Wea Dominick 2004 Weak 1999 116 3061 0.038 0.032 0.045 0.000 3.93
Wea
Clarke 2002 Weak 2000 19 143 0.133 0.086 0.199 0.000 3.13Wea
Wea Gore 2007 Weak 2001 1900 30999 0.061 0.059 0.064 0.000 4.10
Wea Mafi 2013 Weak 2001 32 725 0.044 0.031 0.062 0.000 3.52
Wea Mafi 2013 Weak 2003 15 831 0.018 0.011 0.030 0.000 3.04
Wea Carbone 2013 Weak 2005 2687 7447 0.361 0.350 0.372 0.000 4.10
Wea Mafi 2013 Weak 2005 37 816 0.045 0.033 0.062 0.000 3.59
Wea Curtis 2017 Weak 2007 19572 240750 0.081 0.080 0.082 0.000 4.11
Wea Vincent 2015 Weak 2007 174 1111 0.157 0.136 0.179 0.000 3.97
Wea Fitzcharles 2011 Weak 2008 39 457 0.085 0.063 0.115 0.000 3.59
Wea Henderson 2013 Weak 2008 96 1088 0.088 0.073 0.107 0.000 3.88
Wea Wilson 2015 Weak 2009 30811 238536 0.129 0.128 0.131 0.000 4.11
Wea Zamora-Legoff 2016 Weak 2008 44 501 0.088 0.066 0.116 0.000 3.64
Wea Curtis 2017 Weak 2008 20550 240750 0.085 0.084 0.086 0.000 4.11
Wea Mafi 2013 Weak 2007 38 979 0.039 0.028 0.053 0.000 3.60
Wea Curtis 2017 Weak 2009 21040 240750 0.087 0.086 0.089 0.000 4.11
Wea Curtis 2017 Weak 2010 20061 240750 0.083 0.082 0.084 0.000 4.11
Wea Mafi 2013 Weak 2009 33 700 0.047 0.034 0.066 0.000 3.53
Wea Curtis 2017 Weak 2011 16147 240750 0.067 0.066 0.068 0.000 4.11
Wea Birtwhistle 2015 Weak 2011 9180 29562 0.311 0.305 0.316 0.000 4.11
Wea Perez 2013 Weak 2011 593 8695 0.068 0.063 0.074 0.000 4.07
Wea Curtis 2017 Weak 2012 16636 240750 0.069 0.068 0.070 0.000 4.11
Wea Curtis 2017 Weak 2013 17125 240750 0.071 0.070 0.072 0.000 4.11
Wea Curtis 2017 Weak 2014 17125 240750 0.071 0.070 0.072 0.000 4.11
Wea 0.085 0.072 0.099 0.000
Wea Dominick 2004 Weak combination 1999 342 3061 0.112 0.101 0.123 0.000 24.99
Wea Henderson 2013 Weak combination 2008 166 1088 0.153 0.132 0.175 0.000 24.70
Wea Wilson 2015 Weak combination 2009 35862 238536 0.150 0.149 0.152 0.000 25.24
Wea Perez 2013 Weak combination 2011 480 8695 0.055 0.051 0.060 0.000 25.07
Wea 0.110 0.066 0.178 0.000
Over 0.129 0.117 0.143 0.000
0.00 0.50 1.00















Study name Statistics for each study Weight (Random) Event rate and 95% CI
Event Lower Upper Relative 
Total Total rate limit limit p-Value weight
Turk 1997 1997 17 42 0.405 0.269 0.557 0.220 5.54
Mafi 2013 1999 144 572 0.252 0.218 0.289 0.000 5.90
Mapel 2004 2000 8801 84912 0.104 0.102 0.106 0.000 5.94
Mafi 2013 2001 212 725 0.292 0.260 0.327 0.000 5.91
Mafi 2013 2003 227 831 0.273 0.244 0.304 0.000 5.91
Ashworth 2013 2005 234 715 0.327 0.294 0.363 0.000 5.91
Mafi 2013 2005 245 816 0.300 0.270 0.333 0.000 5.91
Podichetty 2008 2006 283 486 0.582 0.538 0.625 0.000 5.90
Dobscha 2013 2008 864 2431 0.355 0.337 0.375 0.000 5.93
Henderson 2013 2008 122 313 0.390 0.337 0.445 0.000 5.88
Mafi 2013 2007 508 979 0.519 0.488 0.550 0.237 5.92
Edlund 2014 2009 374753 605084 0.619 0.618 0.621 0.000 5.94
Mafi 2013 2009 295 700 0.421 0.385 0.458 0.000 5.91
Mahowald 2005 2010 152 230 0.661 0.597 0.719 0.000 5.86
Young 2011 2010 210 360 0.583 0.532 0.633 0.002 5.89
Romanelli 2017 2012 40062 58925 0.680 0.676 0.684 0.000 5.94
Videla 2017 2012 62 127 0.488 0.402 0.575 0.790 5.80






5.3 The proportion of opioid analgesics prescribed to patients across all diagnoses 
Group by
Diagnosis
Study name Events/Total Statistics for each study
Event Lower Upper Relative 
Total rate limit limit p-Value weight
Chronic back pain Mahowald 2005 152 / 230 0.661 0.597 0.719 0.000 9.04 Moderate 1997 North America
Chronic back pain Mafi 2013 144 / 572 0.252 0.218 0.289 0.000 9.08 Moderate 1999  North America
Chronic back pain Mapel 2004 16581 / 188452 0.088 0.087 0.089 0.000 9.13 Low 2000 North America
Chronic back pain Mafi 2013 212 / 725 0.292 0.260 0.327 0.000 9.10 Moderate 2001 North America
Chronic back pain Mafi 2013 227 / 831 0.273 0.244 0.304 0.000 9.10 Moderate 2003  North America
Chronic back pain Ashworth 2013 234 / 715 0.327 0.294 0.363 0.000 9.10 Low 2005 Europe
Chronic back pain Mafi 2013 245 / 816 0.300 0.270 0.333 0.000 9.10 Moderate 2005 North America
Chronic back pain Podichetty 2008 283 / 486 0.582 0.538 0.625 0.000 9.09 Moderate 2006 North America
Chronic back pain Mafi 2013 508 / 979 0.519 0.488 0.550 0.237 9.11 Moderate 2007  North America
Chronic back pain Mafi 2013 295 / 700 0.421 0.385 0.458 0.000 9.10 Moderate 2009 North America
Chronic back pain Young 2011 210 / 360 0.583 0.532 0.633 0.002 9.07 High 2010 North America
Chronic back pain 0.372 0.207 0.573 0.208
Chronic pain Jensen 2006 64 / 160 0.400 0.327 0.478 0.012 2.80 Moderate 1991 Europe
Chronic pain Castillo 2016 96 / 569 0.169 0.140 0.202 0.000 3.88 Moderate 1995 North America
Chronic pain Turk 1997 81 / 191 0.424 0.356 0.495 0.037 3.09 Moderate 1997 North America
Chronic pain AlMakadma 2013 526 / 1500 0.351 0.327 0.375 0.000 5.36 High 1998 Europe
Chronic pain Cowan 2003 104 / 1392 0.075 0.062 0.090 0.000 4.14 Moderate 1999 Europe
Chronic pain Clarke 2002 47 / 143 0.329 0.257 0.410 0.000 2.51 Moderate 2000 North America
Chronic pain Steinman 2015 269 / 6559 0.041 0.036 0.046 0.000 5.17 Moderate 2000 North America
Chronic pain Beehler 2013 524 / 792 0.662 0.628 0.694 0.000 4.84 Moderate 2006 North America
Chronic pain Fredheim  2014 2204 / 14477 0.152 0.146 0.158 0.000 5.92 Low 2007 Europe
Chronic pain Dobscha 2013 2040 / 5961 0.342 0.330 0.354 0.000 5.87 Low 2008 North America
Chronic pain Henderson 2013 356 / 1088 0.327 0.300 0.356 0.000 5.11 Low 2008 Western Pacific
Chronic pain Edlund 2014 662090 / 1332810 0.497 0.496 0.498 0.000 6.06 Low 2009 North America
Chronic pain Steinman 2015 597 / 6559 0.091 0.084 0.098 0.000 5.60 Moderate 2009 North America
Chronic pain Edlund 2014 700140 / 1405563 0.498 0.497 0.499 0.000 6.06 Low 2010 North America
Chronic pain Park 2016 4707 / 12165 0.387 0.378 0.396 0.000 5.97 Low 2010 North America
Chronic pain Perez 2013 4847 / 8579 0.565 0.554 0.575 0.000 5.94 Moderate 2011 Europe
Chronic pain Edlund 2014 720287 / 1437392 0.501 0.500 0.502 0.008 6.06 Low 2011 North America
Chronic pain Tian 2013 3231 / 7491 0.431 0.420 0.443 0.000 5.92 Low 2011 North America
Chronic pain Videla 2017 126 / 269 0.468 0.409 0.528 0.300 3.63 Moderate 2012 Europe
Chronic pain Romanelli 2017 69935 / 120481 0.580 0.578 0.583 0.000 6.05 Low 2012 North America
Chronic pain 0.334 0.319 0.351 0.000
Fibromyalgia Mohanty 2016 2419 / 8208 0.295 0.285 0.305 0.000 20.36 Moderate 2007 North America
Fibromyalgia Vincent 2015 423 / 1111 0.381 0.353 0.410 0.000 19.94 Moderate 2007 North America
Fibromyalgia Fitzcharles 2011 144 / 457 0.315 0.274 0.359 0.000 19.16 Moderate 2008 North America
Fibromyalgia Robinson 2012 672 / 1700 0.395 0.372 0.419 0.000 20.11 Moderate 2009 North America
Fibromyalgia Margolis 2016 28368 / 64038 0.443 0.439 0.447 0.000 20.43 Moderate 2010 North America
Fibromyalgia 0.365 0.289 0.448 0.002
Headache Mafi 2015 68 / 352 0.193 0.158 0.241 0.000 14.59 Low 1999 North America
Headache Mafi 2015 98 / 585 0.168 0.139 0.200 0.000 17.02 Low 2001 North America
Headache Mafi 2015 134 / 577 0.232 0.200 0.268 0.000 18.35 Low 2003 North America
Headache Mafi 2015 86 / 504 0.171 0.142 0.208 0.000 16.25 Low 2005 North America
Headache Mafi 2015 101 / 522 0.193 0.162 0.230 0.000 17.01 Low 2007 North America
Headache Mafi 2015 93 / 594 0.157 0.130 0.188 0.000 16.78 Low 2009 North America
0.186 0.164 0.210 0.000
60 / 244 0.246 0.196 0.304 0.000 6.94 Moderate 2004 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2005 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2006 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2007 North America
71 / 244 0.291 0.237 0.351 0.000 7.04 Moderate 2008 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2009 North America
155 / 501 0.309 0.270 0.351 0.000 7.57 Moderate 2009 North America
97859 / 240750 0.406 0.405 0.408 0.000 8.10 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2011 North America
72 / 244 0.295 0.241 0.355 0.000 7.05 Moderate 2012 North America
65 / 244 0.266 0.215 0.325 0.000 6.99 Moderate 2013 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2014 North America
75 / 244 0.307 0.253 0.368 0.000 7.07 Moderate 2015 North America
0.295 0.255 0.339 0.000
Neuropathic pain Gore 2007 3464 / 30999 0.112 0.108 0.115 0.000 25.21 Moderate 2001 North America
Neuropathic pain Berger 2012 15444 / 31688 0.487 0.482 0.493 0.000 25.21 Moderate 2006 Europe
Neuropathic pain Sule 2008 17 / 467 0.036 0.023 0.058 0.000 24.42 High 2007 South East Asia
Neuropathic pain Shadd 2015 543 / 1219 0.445 0.418 0.473 0.000 25.17 Moderate 2008 North America
Neuropathic pain 0.199 0.061 0.489 0.043
Osteoarthritis Dominick 2004 1248 / 3061 0.408 0.390 0.425 0.000 13.51 High 1999 North America
Osteoarthritis Rolita 2013 61 / 3731 0.016 0.013 0.021 0.000 10.25 Moderate 2003 North America
Osteoarthritis Wright 2013 151 / 488 0.309 0.270 0.352 0.000 11.54 High 2003 North America
Osteoarthritis Wright 2013 186 / 477 0.390 0.347 0.434 0.000 11.70 High 2006 North America
Osteoarthritis Rolita 2013 3329 / 11012 0.302 0.294 0.311 0.000 13.78 Moderate 2007 North America
Osteoarthritis Wilson 2015 76495 / 238536 0.321 0.319 0.323 0.000 13.90 Moderate 2008 Europe
Osteoarthritis Wright 2013 168 / 422 0.398 0.352 0.446 0.000 11.47 High 2009 North America
Osteoarthritis Birtwhistle 2015 9761 / 29562 0.330 0.325 0.336 0.000 13.86 Low 2011 North America
0.273 0.243 0.305 0.000
5106 / 7447 0.686 0.675 0.696 0.000 100.00 Moderate 2005 North America





































Risk of bias Sampling year RegionGroup by
Diagnosis
Study name Events/Total Statistics for each study
Event Lower Upper Relative 
Total rate limit limit p-Value weight
Chronic back pain Mahowald 2005 152 / 230 0.661 0.597 0.719 0.000 9.04 Moderate 1997 North America
Chronic back pain Mafi 2013 144 / 572 0.252 0.218 0.289 0.000 9.08 Moderate 1999 North America
Chronic back pain Mapel 2004 16581 / 188452 0.088 0.087 0.089 0.000 9.13 Low 2000 North America
Chronic back pain Mafi 2013 212 / 725 0.292 0.260 0.327 0.000 9.10 Moderate 2001 North America
Chronic back pain Mafi 2013 227 / 831 0.273 0.244 0.304 0.000 9.10 Moderate 2003 North America
Chronic back pain Ashworth 2013 234 / 715 0.327 0.294 0.363 0.000 9.10 Low 2005 Europe
Chronic back pain Mafi 2013 245 / 816 0.300 0.270 0.333 0.000 9.10 Moderate 2005 North America
Chronic back pain Podichetty 2008 283 / 486 0.582 0.538 0.625 0.000 9.09 Moderate 2006 North America
Chronic back pain Mafi 2013 508 / 979 0.519 0.488 0.550 0.237 9.11 Moderate 2007 North America
Chronic back pain Mafi 2013 295 / 700 0.421 0.385 0.458 0.000 9.10 Moderate 2009 North America
Chronic back pain Young 2011 210 / 360 0.583 0.532 0.633 0.002 9.07 High 2010 North America
Chronic back pain 0.372 0.207 0.573 0.208
Chronic pain Jensen 2006 64 / 160 0.400 0.327 0.478 0.012 2.80 Moderate 1991 Europe
Chronic pain Castillo 2016 96 / 569 0.169 0.140 0.202 0.000 3.88 Moderate 19 5 North America
Chronic pain Turk 1997 81 / 191 0.424 0.356 0.495 0.037 3.09 Moderate 1997 North America
Chronic pain AlMakadma 2013 526 / 1500 0.351 0.327 0.375 0.000 5.36 High 1998 Europe
Chronic pain Cowan 2003 104 / 1392 0.075 0.062 0.090 0.000 4.14 Moderate 1999 Europe
Chronic pain Clarke 2002 47 / 143 0.329 0.257 0.410 0.000 2.51 Moderate 2000 North America
Chronic pain Steinman 2015 269 / 6559 0.041 0.036 0.046 0.000 5.17 Moderate 2000 North America
Chronic pain Beehler 2013 524 / 792 0.662 0.628 0.694 0.000 4.84 Moderate 2006 North America
Chronic pain Fredheim  2014 2204 / 14477 0.152 0.146 0.158 0.000 5.92 Low 0 7 Europe
Chronic pain Dobscha 2013 2040 / 5961 0.342 0.330 0.354 0.000 5.87 Low 2008 North America
Chronic pain Henderson 2013 356 / 1088 0.327 0.300 0.356 0.000 5.11 Low 2008 Western Pacific
Chronic pain Edlund 2014 662090 / 1332810 0.497 0.496 0.498 0.000 6.06 Low 09 North America
Chronic pain Steinman 2015 597 / 6559 0.091 0.084 0.098 0.000 5.60 Moderate 2009 North America
Chronic pain Edlund 2014 700140 / 1405563 0.498 0.497 0.499 0.000 6.06 Low 201 North America
Chronic pain Park 2016 4707 / 12165 0.387 0.378 0.396 0.000 5.97 Low 2010 North America
Chronic pain Perez 2013 4847 / 8579 0.565 0.554 0.575 0.000 5.94 Moderate 2011 Europe
Chronic pain Edlund 2014 720287 / 1437392 0.501 0.500 0.502 0.008 6.06 Low 2011 North America
Chronic pain Tian 2013 3231 / 7491 0.431 0.420 0.443 0.000 5.92 Low 2011 North America
Chronic pain Videla 2017 126 / 269 0.468 0.409 0.528 0.300 3.63 Moderate 2012 Europe
Chronic pain Romanelli 2017 69935 / 120481 0.580 0.578 0.583 0.000 6.05 Low 2012 North America
Chronic pain 0.334 0.319 0.351 0.000
Fibromyalgia Mohanty 2016 2419 / 8208 0.295 0.285 0.305 0.000 20.36 Moderate 2007 North America
Fibromyalgia Vincent 2015 423 / 1111 0.381 0.353 0.410 0.000 19.94 Moderate 2007 North America
Fibromyalgia Fitzcharles 2011 144 / 457 0.315 0.274 0.359 0.000 19.16 Moderate 2008 North America
Fibromyalgia Robinson 2012 672 / 1700 0.395 0.372 0.419 0.000 20.11 Moderate 2009 North America
Fibromyalgia Margolis 2016 28368 / 64038 0.443 0.439 0.447 0.000 20.43 Moderate 2010 North America
Fibromyalgia 0.365 0.289 0.448 0.002
Headache Mafi 2015 68 / 352 0.193 0.158 0.241 0.000 14.59 Low 1999 North America
Headache Mafi 2015 98 / 585 0.168 0.139 0.200 0.000 17.02 Low 2001 North America
Headache Mafi 2015 134 / 577 0.232 0.200 0.268 0.000 18.35 Low 2003 North America
Headache Mafi 2015 86 / 504 0.171 0.142 0.208 0.000 16.25 Low 2005 North America
Headache Mafi 2015 101 / 522 0.193 0.162 0.230 0.000 17.01 Low 2007 North America
Headache Mafi 2015 93 / 594 0.157 0.130 0.188 0.000 16.78 Low 2009 North America
0.186 0.164 0.210 0.000
60 / 244 0.246 0.196 0.304 0.000 6.94 Moderate 2004 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2005 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2006 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2007 North America
71 / 244 0.291 0.237 0.351 0.000 7.04 Moderate 2008 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2009 North America
155 / 501 0.309 0.270 0.351 0.000 7.57 Moderate 2009 North America
97859 / 240750 0.406 0.405 0.408 0.000 8.10 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2011 North America
72 / 244 0.295 0.241 0.355 0.000 7.05 Moderate 201 North America
65 / 244 0.266 0.215 0.325 0.000 6.99 Moderate 2013 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2014 North America
75 / 244 0.307 0.253 0.368 0.000 7.07 Moderate 201 North America
0.295 0.255 0.339 0.000
Neuropathic pain Gore 2007 3464 / 30999 0.112 0.108 0.115 0.000 25.21 Moderate 2001 North America
Neuropathic pain Berger 2012 15444 / 31688 0.487 0.482 0.493 0.000 25.21 Moderate 2006 Europe
Neuropathic pain Sule 2008 17 / 467 0.036 0.023 0.058 0.000 24.42 High 200 South East Asia
Neuropathic pain Shadd 2015 543 / 1219 0.445 0.418 0.473 0.000 25.17 Moderate 2008 North America
Neuropathic pain 0.199 0.061 0.489 0.043
Osteoarthritis Dominick 2004 1248 / 3061 0.408 0.390 0.425 0.000 13.51 High 1999 North America
Osteoarthritis Rolita 2013 61 / 3731 0.016 0.013 0.021 0.000 10.25 Moderate 2003 North America
Osteoarthritis Wright 2013 151 / 488 0.309 0.270 0.352 0.000 11.54 High 2003 North America
Osteoarthritis Wright 2013 186 / 477 0.390 0.347 0.434 0.000 11.70 High 2006 North America
Osteoarthritis Rolita 2013 3329 / 11012 0.302 0.294 0.311 0.000 13.78 Moderate 2007 North America
Osteoarthritis Wilson 2015 76495 / 238536 0.321 0.319 0.323 0.000 13.90 Moderate 2008 Europe
Osteoarthritis Wright 2013 168 / 422 0.398 0.352 0.446 0.000 11.47 High 2009 North America
Osteoarthritis Birtwhistle 2015 9761 / 29562 0.330 0.325 0.336 0.000 13.86 Low 201 North America
0.273 0.243 0.305 0.000
5106 / 7447 0.686 0.675 0.696 0.000 100.00 Moderate 2005 North America





































Risk of bias Sampling year RegionGroup by
Diagnosis
Study na e Events/Total Statistics for each study
Event Lower Upp r Relative 
Total rate limit limit p-Value weight
Chronic back pain Mahowald 2005 152 / 230 0.66 0.597 0.719 0.000 9.04 Moderate 1997 North America
Chronic back pain Mafi 2013 144 / 572 0.252 0.218 0.289 0.000 9.08 Moderate 1999  North America
Chronic back ain Mapel 2004 16581 / 188452 0.08 0. 87 0.089 0.000 9.13 Low 2000 North America
Chronic back pain Mafi 2013 21  / 725 0.29 0.260 0.327 0.000 9.10 Moderate 2001 North America
Chronic back pain Mafi 2013 227 / 831 0.273 0.244 0.304 0.000 9.10 Moderate 2003  North America
Chronic back pain Ashworth 13 234 / 15 0.327 0.294 0.363 0.000 9.10 Low 2005 Europe
Chronic back pain Mafi 2013 245 / 816 0.300 0.270 0.333 0.000 9.10 Moderate 2005 North America
Chronic back pain Podichetty 2 08 283 / 486 0.58 0.538 0.625 0.000 9.09 Moderate 2006 North America
Chronic back pain Mafi 2013 508 / 79 0.519 0.488 0.550 0.237 9.11 Moderate 2007  North America
Chronic back pain Mafi 2013 295 / 700 0.421 0.385 0.458 0.000 9.10 Moderate 2009 North America
Chronic back pain Young 2011 210 / 60 0.58 0.532 0.633 0.002 9.07 High 2010 North America
Chronic back pain 0.372 0.207 0.573 0.208
Chronic pain Jensen 200 6  / 160 0.400 0.327 0.478 0.012 2.80 Moderate 1991 Europe
Chronic pain Castillo 2016 96 / 569 0.169 0.140 0.202 0.000 3.88 Moderate 1995 North America
Chronic pain Turk 1997 81 / 191 0.424 0.356 0.495 0.037 3.09 Moderate 1997 North America
Chronic pain AlMakadma 013 526 / 500 0.351 0.327 0.375 0.000 5.36 High 1998 Europe
Chronic pain Cowan 2003 1 4 / 1392 0.075 0. 62 0.090 0.000 4.14 Moderate 1999 Europe
Chronic pain Clarke 2002 47 / 143 0.329 0.257 0.410 0.000 2.51 Moderate 2000 North America
Chronic pain Steinman 15 269 / 6559 0.041 0. 36 0.046 0.000 5.17 Moderate 2000 North America
Chronic pain Beehler 2013 524 / 792 0.6 2 0.628 0.694 0.000 4.84 Moderate 2006 North America
Chronic pain Fredheim  14 22 4 / 14477 0.152 0.146 0.158 0.000 5.92 Low 2007 Europe
Chronic pain Dobscha 13 2040 / 5961 0.342 0.330 0.354 0.000 5.87 Low 2008 North America
Chronic pain Henderson 2013 356 / 1088 0.327 0.300 0.356 0.000 5.11 Low 2008 Western Pacific
Chronic pain Edlund 2014 662090 / 1332810 0.497 0.496 0.498 0.000 6.06 Low 2009 North America
Chronic pain Steinman 2 15 597 / 6559 0.091 0. 84 0.098 0.000 5.60 Moderate 2009 North America
Chronic pain Edlund 2 700140 / 1405563 0.498 0.497 0.499 0.000 6.06 Low 2010 North America
Chronic pain Park 2016 47 7 / 12165 0.387 0.378 0.396 0.000 5.97 Low 2010 North America
Chronic pain Perez 2013 4847 / 8579 0.565 0.554 0.575 0.000 5.94 Moderate 2011 Europe
Chronic pain Edlund 14 720287 / 437392 0.501 0.500 0.502 0.008 6.06 Low 2011 North America
Chronic pain Tian 2013 3231 / 7491 0.431 0.420 0.443 0.000 5.92 Low 2011 North America
Chronic pain Videla 2017 126 / 269 0.468 0.409 0.528 0.300 3.63 Moderate 2012 Europe
Chronic pain Romanelli 2017 6993  / 120481 0.580 0.578 0.583 0.000 6.05 Low 2012 North America
Chronic pain 0.3 4 0.319 0.351 0.000
Fibromyalgia Mohanty 2016 2419 / 8208 0.295 0.285 0.305 0.000 20.36 Moderate 2007 North America
Fibromyalgia Vincent 2015 42  / 111 0.38 0.353 0.410 0.000 19.94 Moderate 2007 North America
Fibromyalgia Fitzcharles 2011 144 / 457 0.31 0.274 0.35 0.000 19.16 Moderate 2008 North America
Fibromyalgia Robinson 2012 672 / 1700 0.395 0.372 0.419 0.000 20.11 Moderate 2009 North America
Fibromyalgia Margolis 01 28368 / 64038 0.4 3 0.439 0.447 0.000 20.43 Moderate 2010 North America
Fibromyalgia 0.365 0.289 0.448 0.002
Headache Mafi 2015 68 / 52 0.193 0.158 0.241 0.000 14.59 Low 1999 North America
Headache Mafi 2015 98 / 585 0.168 0.139 0.200 0.000 17.02 Low 2001 North America
Headache Mafi 2015 134 / 577 0.232 0.200 0.26 0.000 18.35 Low 2003 North America
Headache Mafi 2015 86 / 504 0.171 0.142 0.208 0.000 16.25 Low 2005 North America
Headache Mafi 2015 10  / 522 0.19 0.162 0.230 0.000 17.01 Low 2007 North America
Headache Mafi 2015 93 / 594 0.157 0.130 0.188 0.000 16.78 Low 2009 North America
0.186 0.164 0.210 0.000
60 / 244 0.246 0.196 0.304 0.000 6.94 Moderate 2004 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2005 North America
67 / 244 0.275 0.222 0.334 0.000 7.01 Moderate 2006 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2007 North America
71 / 244 0.291 0.237 0.351 0.000 7.04 Moderate 2008 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2009 North America
155 / 501 0.309 0.270 0.351 0.000 7.57 Moderate 2009 North America
97859 / 240750 0.406 0.405 0.408 0.000 8.10 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2010 North America
73 / 244 0.299 0.245 0.360 0.000 7.06 Moderate 2011 North America
7  / 244 0.29 0.241 0.355 0.000 7.05 Moderate 2012 North America
65 / 244 0.266 0.215 0.325 0.000 6.99 Moderate 2013 North America
68 / 244 0.279 0.226 0.338 0.000 7.02 Moderate 2014 North America
75 / 244 0.307 0.253 0.368 0.000 7.07 Moderate 2015 North America
0.295 0.255 0.339 0.000
Neuropathic pain Gore 2007 3464 / 30999 0.1 2 0.108 0.11 0.000 25.21 Moderate 2001 North America
Neuropathic pain Berger 2012 1544  / 31688 0.487 0.482 0.493 0.000 25.21 Moderate 2006 Europe
Neuropathic pain Sule 2008 17 / 467 0.036 0. 23 0.058 0.000 24.42 High 2007 South East Asia
Neuropathic p in Shadd 201 543 / 1219 0.4 5 0.418 0.473 0.000 25.17 Moderate 2008 North America
Neuropathic pain 0.199 0. 61 0.489 0.043
Osteoarthritis Dominick 2004 1248 / 3061 0.408 0.390 0.425 0.000 13.51 High 1999 North America
Osteoarthritis Rolita 2013 61 / 3731 0.016 0. 13 0.021 0.000 10.25 Moderate 2003 North America
Osteoarthritis Wright 2013 151 / 488 0.309 0.270 0.352 0.000 11.54 High 2003 North America
Osteoarthritis Wright 2013 186 / 477 0.390 0.347 0.434 0.000 11.70 High 2006 North America
Osteoarthritis Rolita 201 3329 / 11012 0.302 0.294 0.311 0.000 13.78 Moderate 2007 North America
Osteoarthritis Wilson 2015 76495 / 238536 0.321 0.319 0.32 0.000 13.90 Moderate 2008 Europe
Osteoarthritis Wright 2013 168 / 422 0.398 0.352 0.446 0.000 11.47 High 2009 North America
Osteoarthritis Birtwhistle 20 5 9761 / 29562 0.3 0 0.325 0.336 0.000 13.86 Low 2011 North America
0.273 0.243 0.305 0.000
510  / 7447 0.686 0.675 0.696 0.000 100.00 Moderate 2005 North America
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Appendix 6: Meta-regression results 
 
6.1 Meta-regression to determine study-level factors associated with opioid prescribing to 











6.2 Meta-regression to determine study-level factors associated with opioid prescribing to 



















Appendix 6.3 Adjusted estimates of opioid analgesics prescribed to patients with chronic low 















Meta-regression model was calculated in logit space, adjusted for WHO region, the disclosure of funding, setting 
and year of study sampling. Adjusted mean estimates for each study were back transformed from logit scale to 
















































Proportion (%) of patients with chronic low back pain prescribed opioids over time 
